Evaluation of Tumoral Perfusion Modification by Dynamic Imaging After Neoadjuvant Chemotherapy Combining Gemcitabine and a Hedgehog Inhibitor (Vismodegib) in Patients With Resectable Pancreatic Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Vismodegib (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms NEOPACHI-001
- 07 Jun 2017 Biomarkers information updated
- 07 Jul 2016 Status changed from recruiting to completed.
- 23 Aug 2014 Status changed from not yet recruiting to recruiting, as per European Clinical Trials Database record.